Herbs (Global Traditional) · Jamu
Kumis Kucing (Orthosiphon aristatus) (Orthosiphon aristatus)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Kumis Kucing (Orthosiphon aristatus) is a medicinal plant containing rosmarinic acid and sinensetin that demonstrates α-glucosidase inhibition activity of 62.84% in vitro studies. The herb works through antioxidant pathways and enzyme inhibition mechanisms that may support blood sugar regulation and urinary health.
Kumis Kucing (Orthosiphon aristatus) is a herbaceous plant in the Lamiaceae family native to Southeast Asia, particularly Indonesia and Malaysia, where it grows as a wild or cultivated shrub with distinctive white or purple flowers resembling cat's whiskers. The leaves are harvested, dried, and processed into powders or extracts using water, ethanol, methanol, or ethyl acetate solvents to yield preparations rich in flavonoids, diterpenes, and phenolic acids.
No human clinical trials, RCTs, or meta-analyses were found in the available research. All evidence comes from in vitro phytochemical screening and traditional use documentation, with studies focusing on α-glucosidase inhibition and antioxidant activities of isolated compounds.
No clinically studied dosage ranges available. Traditional preparations use dried leaf powders or water/ethanol extracts, with standardization targeting sinensetin (0.36-4.02 mg/g) and rosmarinic acid (0.06-7.25 mg/g). Consult a healthcare provider before starting any new supplement.
Kumis Kucing exerts its effects primarily through α-glucosidase enzyme inhibition, showing 62.84% inhibitory activity that may slow carbohydrate digestion and glucose absorption. The rosmarinic acid and sinensetin compounds provide antioxidant activity by scavenging free radicals and reducing oxidative stress. Traditional diuretic effects likely occur through increased kidney filtration and sodium excretion pathways.
Current evidence for Kumis Kucing is limited to in vitro laboratory studies demonstrating α-glucosidase inhibition and antioxidant activity. No human clinical trials have been conducted to validate these mechanisms or establish therapeutic dosages. The 62.84% enzyme inhibition activity represents preliminary laboratory findings that require clinical validation. Traditional use data spans centuries but lacks standardized clinical documentation or safety profiles.
Safety data for Kumis Kucing supplementation is limited due to lack of clinical trials. As a traditional diuretic, it may interact with blood pressure medications and diuretics, potentially causing additive hypotensive effects. Individuals with kidney disorders should avoid use due to potential effects on renal function. Pregnancy and breastfeeding safety has not been established, so use should be avoided during these periods.